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ABSTRACT 
 
Objectives Postnatal thyroid dysfunction is common in preterm infants but the relationship between 
mild dysfunction and neurodevelopment is unclear. Our aim is to describe the relationship between 
thyroid function and neurodevelopment.  
 
Design Cohort analysis 
 
Patients 1275 infants born under 31 weeks’ gestation; there were no exclusion criteria 
 
Setting The infants were part of a UK daily iodine supplementation trial. 
 
Main outcomes Thyroid stimulating hormone, thyroid binding globulin and total thyroxine levels 
were measured in dried blood-spots on postnatal days 7, 14, 28 and the equivalent of 34 weeks’ 
gestation.  Neurodevelopment was measured using the Bayley-III scales of infant development at 2 
years of age.  
 
Results No infant was identified as hypothyroid through routine screening. The 3% of infants 
consistently in the top decile of gestationally age-adjusted thyroid stimulating hormone levels had a 
reduction in cognitive score of 7 Bayley units when compared to those not in the top decile (95%CI -
13,-1).  A reduction in motor composite score of 6 units (95%CI -12,<-0.1) and fine motor score of 1 
unit (95%CI -2,-0.1) was also identified.  The 0.7% of infants consistently in the bottom decile of age-
adjusted thyroxine levels had a reduction in motor composite score of 14 units (95%CI -25,-2) and its 
two subset scores, fine and gross motor, of 2 units (95%CI respectively -4.5,<-0.1, and -4.3,-0.3) 
 
Conclusions Preterm infants with consistent ‘mild’ thyroid dysfunction score less well on 
neurodevelopmental tests at 2 years of age.  Many of these infants will not be detected by current 
clinical protocols or screening programs. 
 
250 words 
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INTRODUCTION  
The natural history of transiently raised levels of thyroid stimulating hormone (TSH), with or without 
associated low thyroxine (T4) levels, in preterm infants is complex and affected by factors such as 
maternal iodine status,1 developmental immaturity of endocrine systems,2-5 critical illness,6 and drug 
exposure.7  The incidence of mildly raised TSH levels depends upon the definition, denominator and 
age-group studied, but in population studies it has been reported as 3.3%8 and 6%,9 and in selected 
clinical studies, as high as 22.3%.10  There is no consensus on whether subtle thyroid dysfunction 
should be treated11,12 and its long-term consequences are unclear, as studies are typically 
methodologically restricted.  It has been suggested that infants with transiently raised TSH levels 
may have a high risk of sub-clinical hypothyroidism in childhood4,13 and possibly developmental 
delay,9 although this is not a consistent observation.5,14 The most common neonatal thyroid 
dysfunction in preterm infants is hypothyroxinaemia (low T4 with normal TSH levels), with an 
incidence of between 7-100%15 in infants less than 28 weeks gestation; the wide range of reported 
incidence reflects varying definitions and methodologies. 
A recently completed trial of daily iodide supplementation in infants born <31 weeks gestation with 
neurodevelopmental outcome measured at 2 years of age16  provided us the opportunity to describe 
T4, TSH, and thyroid binding globulin (TBG) distributions in a preterm neonatal cohort. We also 
examined whether abnormal postnatal thyroid function, characterised by a subtle increase in TSH 
and/or a reduction T4, or by a pattern of hypothyroxinaemia, was related to neurodevelopmental 
outcome.  
METHODS 
Infants <31 weeks’ gestation were recruited to a UK trial of iodine supplementation (30µg/kg/day 
from birth to equivalent of 34 weeks’ gestation) with neurodevelopment assessment at 2 years. 
There were no significant differences in neurodevelopmental outcome, or levels of TSH, TBG and T4 
between the arms of the trial16 and so the data were combined.  The trial was approved by Tayside 
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Committee on Medical Research Ethics (08/S0501/31), all other regulatory bodies (18), and all 
families provided informed consent. The trial protocol is available at 
https://www.npeu.ox.ac.uk/downloads/files/i2s2/protocol/I2S2-Protocol.pdf 
 
Data collected 
Infant blood was collected on dried bloodspot cards at postnatal days 7, 14, 28, and 34 weeks’ 
gestational age (had the fetus remained in-utero, referred to hereafter as equivalent gestational 
age), ± 1 day.  Cards were sent to the Amsterdam Neonatal Screening Laboratory for measurement 
of TSH, T4 and TBG17 (for details see Appendix). T4 is expressed as absolute levels and as a standard 
deviation (SD) of the daily mean, which is calculated from the results of approximately 150 cards of 
term and preterm infants; levels ≤-3.0SD are considered abnormal (in term infants). TBG 
concentrations <40 nmol/L is indicative of TBG deficiency.  
TSH, TBG and T4 whole-blood levels reported in this paper were taken specifically for the trial. TSH 
levels were considered raised if ≥6mU/L because many UK laboratories at the time of the trial used 
6mU/L as their cut-off for recall. (0.2% of all UK infants screened have a bloodspot TSH >6mU/L.)  (A 
whole-blood TSH level of 6mU/l is approximately 15mU/l when measured in a serum sample.) We 
recorded the outcome of thyroid function tests, whether or not Levothyroxine therapy was started, 
and type of thyroid dysfunction. 
Definitions  
Two approaches were used when evaluating the hypothalamo-pituitary-thyroid axis and subsequent 
neurodevelopmental outcome.  First, we used deciles, corrected to gestational age subgroup (i.e. 
≤25, 26-27, 28-30 weeks), to investigate the relationships between TSH, TBG and T4, (top TSH decile 
and bottom deciles for T4, TBG and T4/TBG ratio versus the remaining deciles) with 
neurodevelopmental outcome.  Secondly, we categorized infants into mutually exclusive groups as: 
new born screening diagnosis of hypothyroidism, or to study definition of hypothyroid (TSH ≥6 and 
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T4 ≤-3SD), hyperthyrotropinaemic (TSH ≥6mU/L and T4>-3 SD), hypothyroxinaemic (TSH<6mU/L and 
T4≤-3 SD) or euthyroid (TSH<6mU/L and T4>-3 SD).  This strategy addresses the function of the 
hypothalamo-pituitary axis in its entirety rather than TSH or thyroid hormone secretion in isolation.  
Detailed clinical data were collected18 from birth until discharge home or until the equivalent of 36 
weeks’ gestational age. In a previous study investigating thyroid hormones and neurodevelopment 
we identified 26 factors encompassing maternal, intrapartum, neonatal, lifestyle and the assessor, 
which contributed to the variation in neurodevelopment.19,20  The factors with the strongest 
statistical associations and for which we had data in this study were gender, gestation at birth, the 
assessor performing the neurodevelopmental test, the hospital of birth, and the level of nursing care 
reported on the day of blood sampling. The level of nursing care was categorised as high (level 1), 
medium (level 2) or low (level 3) and was used as a proxy for illness severity.6   To this list of factors 
potentially associated with neurodevelopment we included whether or not the infant received 
iodine supplementation (i.e. trial intervention or placebo) in case it had some unexpected subtle 
impact, whether or not the infant received Levothyroxine therapy, and T4/TBG ratio as clinically 
these were also relevant confounders of neurodevelopment in this group of infants.  (The T4/TBG 
ratio is used as a proxy for FT4 concentrations22).  
Outcome measures 
Infants were assessed using the Bayley-III Scales21 at two years of age corrected for prematurity (±1 
month). The Bayley-III Scales provide cognitive, motor composite and language composite scores, 
each with a population mean=100 and SD=15. The latter two scores have two subtests with mean=10 
and SD=3. Infants were assessed using trial personnel specifically trained to use Bayley-III; random 
performances were video-recorded and audited.   
Statistics 
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Infants were included in the analyses for this paper if they had at least one study blood recorded 
Data were imputed for the primary outcome of the trial (i.e. Bayley-III score) following a five point 
protocol.16 
General linear models, specifically univariate analysis of variance were  constructed to evaluate the 
adjusted association of thyroid function, reported on days 7, 14, 28 and at 34 weeks’ equivalent 
gestational age, on Bayley-III scores.  The indices of thyroid function were classified as described 
earlier in the method section and the outcomes were adjusted for the seven cofactors described 
previously.  Significance was specified at p<0.05.  
We predicted that some infants would switch between thyroid categories over the sampling period, 
whilst others would not. We therefore constructed general linear models for the main and subset 
domains of the Bayley-III, which classified thyroid status over the sampling period as consistently 
within the bottom (T4, T4/TBG ratio) or top (TSH) deciles, or consistently as: euthyroid, hypothyroid, 
hyperthyrotropinaemic, hypothyroxinaemic, or as mixed thyroid function where the infant moves 
between categories.  All bloods recorded for an infant (at day 7, 14, 28 and equivalent of 34 weeks’ 
gestation) had to meet the definition for either hypothyroid, hyperthyrotropinaemia, 
hypothyroxinaemia, or euthyroid to be classified as ‘consistent’. To be included in these analyses 
infants had to have two or more study bloods recorded. The Bayley-III outcomes were adjusted for 
the seven variables described in the methods and, if appropriate, the T4/TBG ratio. All analyses were 
undertaken on SPSS version 22.   
 
 
RESULTS 
1275 infants were recruited to the trial (Supplementary Figure 1). One or more bloods were 
recorded for 1222/1259 (97%) infants, 94% (1185/1259) had ≥2 bloods recorded, and 89% 
(1126/1259) had ≥3 bloods recorded. Bayley-III assessments were available for 997 infants. No infant 
was identified as hypothyroid as a part of the routine neonatal blood spot screening programme, 
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either at 5 days post-delivery or as part of repeat screening conducted at 36 weeks’/time of 
discharge. Thus all references to hypothyroid in this paper from this point refer to the study 
definition of hypothyroid (i.e. TSH=>6 and T4=<-3SD) 
Sixty-two percent of infants had one or more TSH or T4 values outwith the reference range during 
the study. T4 and TBG levels and T4/TBG ratios increase as gestation rises and also over time (Table 
1). TSH levels also increase as gestation rises, but peak and flatten at day 14 for infants born ≤25 
weeks, and peak and then fall for infants born ≥26 weeks (Table 1). None of the infants had TBG 
concentrations <40nmol/L. 
Classification of thyroid function that was consistent over ≥2 bloods showed that 3% (27 infants) 
were consistently in the top decile of TSH levels (Table 2); 0.7% were consistently in the bottom 
decile for T4 levels (7 infants) (Table 3); and, 0.2% were consistently in the bottom decile for T4/TBG 
ratio (2 infants) (Supplementary Table 1). Sixty-nine infants (69/1222) had a TSH level ≥6mU/L 
(irrespective of T4 levels). The majority (49/69) of infants had one isolated elevated TSH level, and 
25% (17/69) had two elevated levels (Table 4). Six infants (4.9 per 1000, 6/1222) had elevated TSH 
levels noted for the first time when they were measured at the equivalent of 34 weeks’ gestation 
(see Appendix).  
Classification of thyroid function that was consistent over ≥2 study bloods by thyroid category 
showed that the majority (670/1185) of infants switch categories (which represents 4 to 11 weeks in 
this cohort of infants).    No infant was consistently hypothyroid or hyperthyrotropinaemic, 5% 
(65/1185) were consistently hypothyroxinaemic, and 38% (450/1185) were consistently euthyroid 
(Supplementary Fig 1); 0.3% (4/1185) were consistently in the bottom decile for T4/TBG ratio.   
Bayley-III outcomes 
The cognitive score for infants consistently in the top decile for TSH levels was 7 Bayley units lower 
(95%CI -13, -1) compared to those who were never in the top decile. There was also a reduction in 
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the motor composite score of 6 units (95%CI -12,-0.012) and the fine motor subset score of 1 unit 
(95%CI -2,-0.1) (Table 2). For infants consistently in the bottom decile of T4, the motor composite 
score was reduced by 13 units (95%CI -25,-2) compared to those who were never in the bottom 
decile. This deficit was contributed by both the fine (2 units 95%CI -4.5,-0.04) and gross (2 units 
95%CI -4.3,-0.3) motor subset scores (Table 3).  
Infants in the top decile for TSH on day 14 (compared to those not in that decile) had lower cognitive 
scores, lower expressive language scores on day 7 and day 14, and lower fine motor scores on day 
14 (Supplementary Tables 2-8). Infants in the bottom decile for T4 (compared to those not in that 
decile) had significantly lower cognitive, motor composite and gross motor scores on day 14, 
(Supplementary Tables 2-8). 
Using adjusted regression models, no infants were consistently hypothyroid or 
hyperthyrotropinaemic. Infants classified as consistently hypothyroxinaemic, compared to those 
who were consistently euthyroid, scored 8 units lower on the cognitive score (95%CI -14,-3), 9 units 
lower on the motor composite score (95%CI -15,-4), 11 units lower on the language composite score 
(95%CI -17,-4) and lower on all subtest domains (Table 5).   
Infants classified as hypothyroid on day 7 scored significantly lower on all Bayley-III main, and three 
of the four subtest domains compared with infants classified as euthyroid. There were two strong 
significant associations: the classification of hypothyroid on day 7 with the Bayley-III cognitive score 
(a reduction of 21 units compared with the euthyroid group), and the fine motor subtest score (a 
reduction of 3 units compared with the euthyroid group) (Supplementary Tables 9-11). Of the seven 
infants categorized as hypothyroid on day 7, five had TSH levels <11.0 mU/l, one infant’s TSH was 
11.0 mU/l and one infant’s TSH was 22.0 mU/l.   
For more clinical characteristics of the infants, see Appendix.  
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DISCUSSION 
This analysis has highlighted two important observations.  First, when compared to a euthyroid 
state, consistent hypothyroxinaemia (i.e. measured on at least two occasions), but not isolated 
episodes of low T4, is associated with significantly lower (8-11 points) Bayley-III scores in all the 
domains: cognitive, motor and language. Secondly, isolated mildly raised TSH levels (≥6mU/L) are 
associated with significantly lower Bayley-III scores when compared to euthyroid. 
Several studies19,24-26 have reported adverse associations between neurodevelopment and low 
postnatal T4 levels but it has also been queried whether hypothyroxinaemia is simply an 
epiphenomenon of prematurity and illness.29  Observational studies cannot provide the definitive 
answers of a randomised controlled trial, but designing a trial to answer this question is very 
challenging.  Our data suggest that trials in this field should target only those infants who are 
consistently hypothyroxinaemic. Pragmatically, such infants are difficult to identify as they represent 
a small proportion of preterm infants (5% in our cohort) and agreeing a definition for 
hypothyroxinaemia/low T4 is not straightforward. There is an appreciable gestational-age gradient in 
levels of T423 and T4 levels also vary according to the postnatal age at sampling and the media used 
(whole blood, plasma, serum).15, 23 Furthermore, to preserve neurodevelopment hypothyroxinaemia 
needs to be treated quickly as evidence from managing congenital hypothyroidism33 shows that 
replacement therapy must start within two weeks in order to optimise neurodevelopment. Use of 
blood-spot cards may provide a rapid way to identify hypothyroxinaemia and to facilitate trials and 
management. (It is important to highlight that hypothyroxinaemia is separate from the congenital 
hypothyroidism due to dysgenesis or dyshormonogenesis that screening programmes were designed 
to detect.) 
We optimised the strength of our observational design by adjusting for many of the key contributors 
to neurodevelopment in a preterm population.  It is relevant therefore that the association between 
low T4 levels and Bayley-III scores remained significant following adjustment for gender, gestation at 
birth and level of sickness. The inclusion of gestation in the regression model was important as it 
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counteracts the impact of using T4 levels derived from term and preterm infants in the definition of 
hypothyroxinaemia.  The data were also adjusted for study relevant factors such as treatment with 
Levothyroxine and daily iodine supplementation, as well as methodological factors such as assessor 
variability.20  
In this large preterm cohort, 5.7% of infants had mildly raised (≥6mU/L) TSH levels. This proportion 
seems low when compared, for example, to the 6% found by Cuestas9 in an exclusively term cohort, 
but is likely due to differences in the day of testing, and the use of whole-blood rather than serum. 
Mildly raised TSH levels seem to be important as we found associations with neurodevelopment 
whether the TSH levels were defined by categories of thyroid function or by deciles. An association 
between borderline bloodspot TSH concentrations and poorer neurodevelopmental outcome has 
similarly been reported in a large population of primarily term infants.30 Evidence of poorer cognitive 
development and motor development, and in particular fine motor development, with mildly raised 
levels of postnatal TSH now need to be confirmed in other cohorts with intervention trials a logical 
next step.  
This study has limitations. The use of 6mU/L as a cut-off to categorise hypothyroidism is lower than 
many national screening programmes which more typically use 10mU/L or higher. We chose 6mU/L 
because several UK laboratories at the time of the trial used 6mU/L as their cut-off for recall. This 
cut-off corresponded to the 97.3%ile of TSH levels at the Amsterdam Screening Laboratory during 
the time of the trial and lies around the 99.8th centile on a UK TSH screening program.31 Fluctuations 
in TSH levels in response to iodine (the trial intervention) are well recognized and may be more 
pronounced in our cohort if the mothers were mildly iodide deficient, which is likely.32  
The definitions of thyroid function used in this paper are those generally applied to term infants, 
who do not have the biochemical patterns characteristic of preterm infants. Preterm infants are 
often critically ill, which may alter thyroid function and thyroid binding proteins. We included a 
measure of illness level in the regression models, which we showed previously to be a good 
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summary indicator,6 and also the T4/TBG ratios in an attempt to control for the preterm infants’ 
thyroid function. Several other important confounding measures of neurodevelopment were 
controlled for, which adds weight to our observations.  
In summary, for the majority of infants in this study cohort, postnatal thyroid dysfunction was 
restricted to an isolated episode.  No infants were consistently hypothyroid or 
hyperthyrotropinaemic; 38% were euthyroid throughout the sampling period and 5% were 
consistently hypothyroxinaemic. Infants with TSH levels consistently in the top decile or categorised 
as hypothyroid specifically on postnatal day 7 performed worse on the Bayley scores than those 
categorised with mixed dysfunction or euthyroid. A small cohort of infants was consistently 
hypothyroxinaemic and this was associated with appreciably worse outcomes than euthyroid infants 
on all Bayley-III domains. Hypothyroxinaemia in preterm infants does not appear to be a benign 
disorder on the basis of the associations that we have identified, and the potential role of thyroxine 
supplementation in this group of infants requires further investigation.28  
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WHAT’S KNOWN ON THIS SUBJECT  
• The natural history of transiently raised levels of thyroid stimulating hormone, with or without 
associated low total thyroxine levels, in preterm infants is complex 
• Fluctuations in postnatal thyroid function are common in preterm infants, but the associated 
patterns and their relationship to longer term neurodevelopment is unclear  
• There is no consensus on whether hypothyroxinaemia is an independent clinical entity 
 
WHAT THIS STUDY ADDS 
• Preterm infants with higher TSH concentrations at one end of the continuum 
have poorer neurodevelopment at two years. 
• Consistent hypothyroxinaemia is associated with poor neurodevelopment at 
two years of age.  Isolated postnatal hypothyroxinaemia in preterm infants is 
not associated with adverse neurodevelopment. 
• Many of these infants will not be detected by current clinical protocols or screening 
programs for congenital hypothyroidism. 
 
 
 
 
 
  
14 
 
REFERENCES 
1. Zimmerman MB  Iodine deficiency.  Endo Rev 2009;30:376-408.  
 
2. American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics, Rose 
SR; American Thyroid Association, Public Health Committee; Lawson Wilkins Pediatric Endocrine 
Society, Brown RS  Update of newborn screening and therapy for congenital hypothyroidism.  
Pediatr 2006;117:2290-2303. 
 
3. Parks JS, Lin M, Grosse S, et al  The impact of transient hypothyroidism on the increasing rate of 
congenital hypothyroidism in the United States.  Pediatr 2010;125:S54-S63. 
   
4. Calaciura F,  Motta RM, Miscio G, et al  Subclinical hypothyroidism in early childhood: a frequent 
outcome of transient neonatal hyperthyrotropinemia.  J Clin Endocrinol Metab 2002;87:3209-3214. 
 
5. Ünüvar T, Demir K, Abac A, et al  The role of initial clinical and laboratory findings in infants with 
hyperthyrotropinaemia to predict transient or permanent hypothyroidism.  J Clin Res Pediatr 
Endocrinol 2013;5:170-173. 
 
6. Simpson J, Williams FLR, Delahunty C, et al  with collaboration from the Scottish Preterm Thyroid 
Group  Serum thyroid hormones in preterm infants and relationships to indices of severity of 
intercurrent illness. J Clin Endocrinol Metab 2005;90:1271-9. 
 
7. Williams FLR, Ogston SA, van Toor H, et al Serum thyroid hormones in preterm infants: 
associations with postnatal illnesses and drug usage.  J Clin Endocrinol Metab 2005;90:5954-
5963. 
 
8. Lazar L, Ben-David Frumkin R, Battat E, et al. Natural history of thyroid function tests over 5 
years in a large pediatric cohort.  J Clin Endocrinol Metab 2009;94:1678–1682. 
9. Cuestas E, Gaido MI, Capra RH Transient neonatal hyperthyrotropinemia is a risk factor for 
developing persistent hyperthyrotropinaemia in childhood with repercussion on developmental 
status.  Eu J Endocrinol 2015;172:483-490.   
10. Oren A, Wang MK, Brnjac L, et al  Mild neonatal hyperthyrotropinemia: 10-year experience suggests 
the condition is increasingly common but often transient.  Clin Endocrinol 2013;79:832-837. 
 
11. O’Grady MJ, Cody D  Subclinical hypothyroidism in childhood.  Arch Dis Child 2011;96:280-284  
 
12. Wassner AJ, Brown RS  Hypothyroidism in the newborn period.  Curr Opin Endocrinol Diabetes Obes 
2013;20:449-454. 
 
13. Daliva A, Linder B, DiMartino-Nardi J, et al  Three- year follow-up of borderline congenital 
hypothyroidism.  J Pediatr 2000;136:53-56. 
 
14. Demeril F, Bideci A, Çamurdan Mo et al  L-thyroxin treatment in infants with 
hyperthyrotropinaemia: 4-year experience.  Int J Clin Pract 2007;61:1333-1336. 
 
15. Williams FLR, Hume R  The measurement, definition, aetiology and clinical consequences of 
neonatal transient hypothyroxinaemia.  Ann Clin Biochem 2011;48:7-22. 
 
 
15 
 
16. Williams FLR, Ogston SA, Hume R, et al, and the I2S2 consortium  Supplemental Iodide for 
Preterm Infants and Developmental Outcomes at 2 years: an RCT.  Pediatrics 2017;139(5) pii: 
e20163703. doi.org/10.1542/peds.2016-3703. 
 
17. Elvers LH, Loeber JG., Verkerk PH  Thyroxine-binding globulin determination as an extra parameter 
in congenital hypothyroidism screening. Proc. 3rd meeting of ISNS (Levy HL, Mermos RJ, Grady GF 
eds) Boston 1996:250-252. 
 
18. Williams FLR, Hume R, Ogston SA, et al  A summary of the iodine supplementation study protocol 
(I2S2); a UK multicentre randomised controlled trial in preterm infants.  Neonatology 
2014;105:282-9. 
 
19. Delahunty C, Falconer S, Hume R, et al and the Scottish Preterm Thyroid Group  Levels of 
neonatal thyroid hormone in preterm infants and neurodevelopmental outcome at 5½ years: 
Millennium cohort study. J Clin Endocrinol Metab 2010;95:4898-908. 
 
20. Khalid R, Willatts P Williams FLR  Do studies reporting infant neurodevelopment adjust for the 
variability of assessors? Dev Med Child Neurol 2016;58:131–137. 
 
21. Bayley N 2005 Bayley scales of infant and toddler development®, Third Edition (Bayley-III®)  
 
22. Boelen A, van Veen M, Verkerk PH, et al  Measuring free thyroxine levels in neonatal heel-prick 
samples. Clin Chim Acta 2013;423:51-5. 
 
23. Williams FLR, Simpson J, Delahunty C, et al  Developmental trends in cord and postpartum 
serum thyroid hormones in preterm infants.  J Clin Endocrinol Metab 2004;89:5314-5320. 
 
24. Van Wassenaer A, Kok JH, de Vijlder JJM, et al  Effects of thyroxine supplements on neurologic 
development in infants born at less than 30 weeks’ gestation.  N Engl J Med 1997;336:21-26. 
 
25. Den Ouden AL, Kok JH, Verkerk PH, et al  The relation between neonatal thyroxine levels and 
neurodevelopmental outcome at age 5 and 9 years in a national cohort of very preterm and/or 
very low birth weight infants. Pediatr Res 1996;39:142-5. 
 
26. Reuss ML, Paneth N, Pinto-Martin JA, et al  The relation of transient hypothyroxinemia in preterm 
infants to neurologic development at two years of age. N Engl J Med 1996;334:821-7. 
 
27. Ng SM, Turner MA, Gamble C, et al  An explanatory randomised placebo controlled trial of 
levothyroxine supplementation for babies born <28 weeks’ gestation: results of the TIPIT trial.  
Trials 2013;14:211-220. 
 
28. van Wassenaer-Leemhuis A,  Ares A, Golombek S, et al  Thyroid hormone supplementation in 
preterm infants born before 28 weeks gestational age and neurodevelopmental outcome at age 
36 months. Thyroid 2014;24:1162-1170. 
 
29. Fisher DA  Hypothyroxinaemia in premature infants: is thyroxine treatment necessary? Thyroid 
1999;9;715-720. 
 
 
30. Lain SJ, Bentley JP, Wiley V, et al  Associations between borderline neonatal thyroid-stimulating 
hormone concentrations and educational and developmental outcomes: a population-based 
16 
 
record-linkage study. Lancet Diabetes Endocrinol 2016 http://dx.doi.org/10.1016/S2213-
8587(16)30122-X 
 
31. Korada SM, Pearce M, WardPlatt MP, et al  Difficulties in selecting an appropriate neonatal thyroid 
stimulating hormone (TSH) screening threshold.  Arch Dis Child 2010;95:169-173 
 
32. Combet E, Bouga M, Pan B, et al  Iodine and pregnancy- a UK cross-sectional survey of dietary 
intake, knowledge and awareness. Brit J Nutr 2015;114:108-117. 
 
33. Bonger-Schokking JJ, Koot HM, Wiersma D, et al  Influence of timing and dose of thyroid 
hormone replacement on development in infants with congenital hypothyroidism.  J Pediatr 
2000;136:292-7. 
17 
 
TABLE 1: Distributions of T4, TSH, TBG and T4/TBG ratio by day of sampling and gestational age-group; mean 
(standard deviation) number 
 
Gestational weeks Day 7 blood Day 14 blood Day 28 blood ≡Week 34 blood 
T4 nmol/l     
≤25 weeks 18.0 (8.6) 241 22.4 (11.6) 208 31.9 (13.3) 196 45.1 (14.0) 180 
26-27 weeks 26.4 (10.2) 311 32.8 (12.7) 309 39.9 (14.6) 297 44.0 (14.8) 290 
28-30 weeks 36.5 (13.6) 617 43.2 (14.2) 625 47.3 (15.8) 585 49.3 (14.7) 541 
     
TSH mU/l      
≤25 weeks 1.3 (0.8) 241 1.6 (1.2) 208 1.6 (1.3) 196 1.6 (1.1) 180 
26-27 weeks 1.4 (1.4) 311 1.9 (2.5) 309 1.7 (1.4) 296 1.5 (1.1) 290 
28-30 weeks 1.8 (1.4) 613 1.9 (1.8) 625 1.6 (1.3) 584 1.6 (1.2) 541 
     
TBG nmol/l     
≤25 weeks 115.6 (40.1) 239 144.0 (46.6) 208 169.7 (54.0) 195 198.0 (58.4) 179 
26-27 weeks 131.9 (40.8) 311 155.1 (47.6) 307 170.1 (51.2) 297 179.3 (59.9) 290 
28-30 weeks 146.5 (45.7) 610  162.9 (48.9) 624 174.0 (53.2) 584 176.2 (52.5) 541 
     
T4/TBG ratio     
≤25 weeks 14.5 (5.5) 239 13.2 (4.6) 208 14.7 (8.2) 195 16.2 (4.5) 179 
26-27 weeks 16.1 (5.3) 311 16.0 (5.3) 307 17.0 (4.9) 297 17.7 (5.7) 290 
28-30 weeks 18.3 (5.1) 610 18.9 (6.6) 624 18.9 (5.0) 584 19.4 (5.1) 541 
     
 
  
18 
 
TABLE 2: Adjusted1 linear regression models of TSH levels which were consistent over at least two 
study bloods and the Bayley-III main and subtest domains 
Bayley-III main domains N Effect estimate T statistic p value 95% confidence interval 
Lower higher 
Cognitive Score  
Consistently top decile TSH 
Mixed dysfunction 
Never in top decile 
  
27 
474 
489 
 
-6.9 
-1.5 
reference 
 
-2.266 
-1.521 
 
0.024 
0.129 
 
-12.9 
-3.5 
 
-0.9 
0.4 
Motor Composite Score  
Consistently top decile TSH 
Mixed dysfunction 
Never in top decile 
 
 27 
 474 
 488 
 
-5.8 
-0.6 
reference 
 
-1.967 
-0.583 
 
 
0.050 
0.560 
 
-11.7 
-2.5 
 
<-0.1* 
1.3 
Language Composite Score  
Consistently top decile TSH 
Mixed dysfunction 
Never in top decile 
  
 27 
 473 
 488 
 
-5.3 
-2.1 
reference 
 
-1.528 
-1.912 
 
0.127 
0.056 
 
-12.0 
-4.3 
 
1.5 
0.1 
Receptive Language Subtest 
Consistently top decile TSH 
Mixed dysfunction 
 Never in top decile 
 
 27 
 473 
 488 
 
-0.7 
-0.2 
reference 
 
-1.179 
-1.143 
 
0.239 
0.253 
 
-1.9 
-0.6 
 
0.5 
0.2 
Expressive Language Subtest 
Consistently top decile TSH 
Mixed dysfunction 
 Never in top decile 
 
 27 
 473 
 487 
 
-1.1 
-0.5 
 
-1.719 
-2.606 
 
0.086 
0.009 
 
-2.3 
-0.9 
 
0.2 
-0.1 
Fine Motor Subtest 
Consistently top decile TSH 
Mixed dysfunction 
 Never in top decile 
 
 27 
 474 
 487 
 
-1.3 
-0.3 
reference 
 
-2.165 
-1.436 
 
0.031 
0.151 
 
-2.4 
-0.6 
 
-0.1 
0.1 
Gross Motor Subtest 
Consistently top decile TSH 
Mixed dysfunction 
 Never in top decile 
 
 27 
 473 
 489 
 
-0.7 
0.1 
reference 
 
-1.215 
0.554 
 
0.224 
0.580 
 
-1.7 
-0.2 
 
0.4 
0.4 
1 adjusted for gender, gestational age, level of nursing care required on day 14, whether or not in receipt of iodine supplement, whether or 
not treated with L-Thyroxine during the neonatal period or at 2 years of age, assessor and hospital of birth 
*Actual figure -0.012  
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TABLE 3: Adjusted1 linear regression models of T4 levels which were consistent over at least two study bloods 
and the Bayley-III main and subtest domains 
Bayley-III main domains N Effect estimate T statistic p value 95% confidence interval 
Lower higher 
Cognitive Score  
Consistently bottom decile T4 
Mixed dysfunction 
Never in bottom decile 
 
 7 
 239 
 744 
 
-9.2 
-1.8 
reference 
 
-1.556 
-1.495 
 
0.120 
0.135 
 
-20.8 
-4.1 
 
2.4 
0.6 
Motor Composite Score  
Consistently bottom decile T4 
Mixed dysfunction 
Never in bottom decile 
 
 7 
 239 
 743 
 
-13.4 
-0.8 
reference 
 
-2.336 
-0.675 
 
0.020 
0.500 
 
-24.6 
-3.0 
 
-2.1 
1.5 
Language Composite Score  
Consistently bottom decile T4 
Mixed dysfunction 
Never in bottom decile 
 
 7 
 238 
 743 
 
-10.6 
-1.1 
reference 
 
-1.599 
-0.814 
 
0.110 
0.416 
 
-23.7 
-3.7 
 
2.4 
1.5 
Receptive Language Subtest 
Consistently bottom decile T4 
Mixed dysfunction 
 Never in bottom decile 
 
 7 
 238 
 743 
 
-1.9 
-0.4 
reference 
 
-1.585 
-1.512 
 
 
0.113 
0.131 
 
-4.2 
-0.8 
 
0.5 
0.1 
Expressive Language Subtest 
Consistently bottom decile T4 
Mixed dysfunction 
 Never in bottom decile 
 
 7 
 238 
 742 
 
-1.8 
<-0.1 
reference 
 
-1.445 
-0.135 
 
0.149 
0.893 
 
-4.1 
-0.5 
 
0.6 
0.5 
Fine Motor Subtest 
Consistently bottom decile T4 
Mixed dysfunction 
 Never in bottom decile 
 
 7 
 239 
 742 
 
-2.2 
<0.1 
reference 
 
-1.988 
0.178 
 
0.046 
0.859 
 
-4.5 
-0.4 
 
<-0.1* 
0.5 
Gross Motor Subtest 
Consistently bottom decile T4 
Mixed dysfunction 
 Never in bottom decile 
 
 7 
 238 
 744 
 
-2.3 
-0.3 
reference 
 
-2.229 
-1.482 
 
0.026 
0.139 
 
-4.3 
-0.7 
 
-0.3 
0.1 
1 adjusted for gender, gestational age, level of nursing care required on day 14, whether or not in receipt of iodine supplement, whether or 
not treated with L-Thyroxine during the neonatal period or at 2 years of age, assessor and hospital of birth 
*Actual figure -0.04  
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TABLE 4: Number of infants with a raised TSH (≥6mu/l) levels by day of blood sampling and subsequent raised 
TSH levels*.   
Blood sampling day 1 isolated raised 
TSH level 
2 raised 
TSH levels 
3 raised 
TSH levels 
4 raised TSH 
levels 
Total number of infants with a first 
raised TSH level per day: incidence 
data 
Day 7 13 5 2 0 20 
Day 14 19 8 1 n/aA 28 
Day 28 11 4 n/aA n/aA 15 
34 weeks’ gestation 6 n/aA n/aA n/aA 6 
Total  49 17 3 0  69 
A  n/a not applicable as it is not possible to obtain this many tests  
* for example on Day 7 there were 20 infants with raised TSH levels of whom 13 had an isolated raised level on 
day 7, 5 infants had two raised levels (on day 7 and either day 14/28/or 34 wks), and 2 infants had three raised 
levels (on day 7, and two others from days 14/28/or 34 wks) 
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TABLE 5: Adjusted1 linear regression models of thyroid function which was consistent over at least two study 
bloods and the Bayley-III main and subtest domains 
Bayley-III main domains N Effect estimate T statistic p value 95% confidence interval 
Lower higher 
Cognitive Score  
Hypothyroxinaemic 
Mixed dysfunction 
Euthyroid 
 
31 
561 
398 
 
-8.4 
-2.1 
reference 
 
-2.818 
-1.864 
 
0.005 
0.063 
 
-14.3 
-4.3 
 
-2.6 
0.1 
Motor Composite Score  
Hypothyroxinaemic 
Mixed dysfunction 
Euthyroid 
 
31 
560 
398 
 
-9.4 
-1.6 
reference 
 
-3.262 
-1.440 
 
0.001 
0.150 
 
-15.1 
-3.7 
 
-3.8 
0.6 
Language Composite Score  
Hypothyroxinaemic 
Mixed dysfunction 
Euthyroid 
 
31 
560 
397 
 
-10.7 
-1.8 
reference 
 
-3.175 
-1.446 
 
0.002 
0.149 
 
-17.2 
-4.3 
 
-4.1 
0.6 
Receptive Language Subtest 
Hypothyroxinaemic 
Mixed dysfunction 
 Euthyroid 
 
31 
560 
397 
 
-1.8 
-0.4 
reference 
 
-2.927 
-1.788 
 
0.004 
0.074 
 
-2.9 
-0.9 
 
-0.6 
<0.1 
Expressive Language Subtest 
Hypothyroxinaemic 
Mixed dysfunction 
 Euthyroid 
 
31 
559 
397 
 
-1.9 
-0.2 
reference 
 
-3.132 
-1.013 
 
0.002 
0.311 
 
-3.1 
-0.7 
 
-0.7 
0.2 
Fine Motor Subtest 
Hypothyroxinaemic 
Mixed dysfunction 
 Euthyroid 
 
31 
559 
398 
 
-1.8 
-0.3 
reference 
 
-3.184 
-1.213 
 
0.001 
0.226 
 
-2.9 
-0.7 
 
-0.7 
0.2 
Gross Motor Subtest 
Hypothyroxinaemic 
Mixed dysfunction 
 Euthyroid 
 
31 
560 
398 
 
-1.3 
-0.2 
reference 
 
-2.587 
-1.227 
 
 
0.010 
0.220 
 
-2.4 
-0.6 
 
-0.3 
0.1 
1 adjusted for gender, gestational age, level of nursing care required on day 14, whether or not in receipt of iodine supplement, whether or 
not treated with L-Thyroxine during the neonatal period or at 2 years of age, assessor and hospital of birth 
 
 
 
 
 
 
 
 
 
 
 
